Sunday, April 28, 2013 10:00:39 PM
Homebuilder
If I may comment on your response to JL .
I currently email with 4 different Cardiologists at 3 different hospitals ..Some are clients / friends , the others are research at UCSF and my own Cardiologist at Kaiser .
JL is very right on regards his comments on inflammation particularly in regards to coronary artery plaque build up.
I have plaque build up ...not enough for stents ..( I've had a cardiac cath ) ...and Pre flu season every year Kaiser is on me relentlessly about having a flu shot ....why ...as they explain , flu causes inflammation and they are concerned that will cause my arterial plaques to rupture .
So drugs that reduce inflammation for those with known CAD are very much in focus .
Regarding your other comments about TG's around 200 .....every Cardiologist I know will insist you try to lower them by diet and exercise alone . It's only with high risk patients such as myself that are already max'd out on statins where prescriptions are considered.
One can argue with JL about his expectations for stock price , sale of co etc ..but in my experience he is very current on where treatment of CAD ( coronary heart disease ) is going ....and increasingly IMHO it's being focused on the role of inflammation
I do not currently have a position in AMRN , however I am encouraged by todays scrip numbers and may restart a position tomorrow .
GL
Akanz
If I may comment on your response to JL .
I currently email with 4 different Cardiologists at 3 different hospitals ..Some are clients / friends , the others are research at UCSF and my own Cardiologist at Kaiser .
JL is very right on regards his comments on inflammation particularly in regards to coronary artery plaque build up.
I have plaque build up ...not enough for stents ..( I've had a cardiac cath ) ...and Pre flu season every year Kaiser is on me relentlessly about having a flu shot ....why ...as they explain , flu causes inflammation and they are concerned that will cause my arterial plaques to rupture .
So drugs that reduce inflammation for those with known CAD are very much in focus .
Regarding your other comments about TG's around 200 .....every Cardiologist I know will insist you try to lower them by diet and exercise alone . It's only with high risk patients such as myself that are already max'd out on statins where prescriptions are considered.
One can argue with JL about his expectations for stock price , sale of co etc ..but in my experience he is very current on where treatment of CAD ( coronary heart disease ) is going ....and increasingly IMHO it's being focused on the role of inflammation
I do not currently have a position in AMRN , however I am encouraged by todays scrip numbers and may restart a position tomorrow .
GL
Akanz
Recent AMRN News
- Earnings Report Shows Narrowing Losses as Amarin (AMRN) Advances Partner-Led Growth Strategy • IH Market News • 04/29/2026 02:19:17 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/29/2026 11:06:34 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 11:05:15 AM
- Amarin Reports 2026 First Quarter Financial Results • GlobeNewswire Inc. • 04/29/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
